EVis Bioscience develops innovative gene delivery systems for targeted and personalized medicine. This includes extracellular vesicles, synthetic lipid nanoparticles, and their hybrids.

Based in Zürich, the ETH spin-off aims to provide an alternative approach to viral vectors for treating genetic disorders.

Further, the company offers sub-licenses of its vehicle to Pharma Companies and/or Research Labs that intend to develop gene-based formulations for specific medical applications. 

The BSL-Class 2 laboratory is equipped with
• Microfluidics
• Dynamic Light Scattering
• Nanoparticle Tracking Analysis
• Nano Flow Cytometry
• Cell culture facilities
• Advanced microscopy techniques and animal facilities through scientific collaboration with the University of Zürich

For more information, please visit our website: www.evisbioscience.com

EVis Bioscience AG

Org chart

Teams

Offices